NC
RLAY icon

NinePointTwo Capital’s Relay Therapeutics RLAY Stock Holding History

NinePointTwo Capital’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,907
Closed -$287K – 311
2023
Q2 		$287K Buy
+22,907
New +$285K 0.11% 66
2023
Q1 		– Sell
-14,410
Closed -$215K – 302
2022
Q4 		$215K Buy
+14,410
New +$276K 0.09% 97
2022
Q2 		– Sell
-17,670
Closed -$528K – 241
2022
Q1 		$528K Buy
+17,670
New +$429K 0.14% 40

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NinePointTwo Capital's RLAY Position: Q3 2023 in Review

NinePointTwo Capital sold out of Relay Therapeutics (RLAY) in Q3 2023, closing a stake of 22,907 shares — an estimated $287K sold.

NinePointTwo Capital first reported a position in RLAY in Q1 2022 and held it in 3 quarters. The position peaked at $528K in Q1 2022. 172 funds tracked by Wall St. Rank hold RLAY as of Q3 2023.

  • NinePointTwo Capital reported no remaining Relay Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 22,907 Relay Therapeutics shares in Q3 2023, an estimated $287K.
  • NinePointTwo Capital first reported a position in Relay Therapeutics in Q1 2022 and held it in 3 quarters.
  • NinePointTwo Capital's Relay Therapeutics position peaked at $528K in Q1 2022.
  • 172 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.